Using brain imaging to predict treatment response in patients with brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with brain metastases who are scheduled to receive radiation treatment. Participants will undergo CT and MRI scans before and after their treatment to measure specific biomarkers that may indicate how well they will respond to the therapy. The goal is to validate the predictive abilities of these imaging biomarkers, which could help tailor treatment plans for better outcomes. Conducted at the Princess Margaret Cancer Center, this single-center phase II study aims to enroll up to 90 patients over a two-year period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases)
* At least one index lesion with diameter \> 1cm and without imaging evidence of hemorrhage
* Patients age \> 18 years of age
* Patients planned for RT to brain metastases
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Previous Whole Brain Radiotherapy
* Previous radiosurgery to the index lesion
* Individuals unable to undergo contrasted MRI for whatever reason

Where it's running

• University Health Network
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Catherine Coolens, Ph. D — Princess Margaret Cancer Center - UHN
• Study coordinator: David Shultz, M.D., Ph. D
• Email: david.shultz@rmp.uhn.on.ca
• Phone: 416-946-6899

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

• AI-assisted diagnosis for malignant brain tumors

  This project will test an AI system that uses routine preoperative MRI scans to automatically segment and classify malignant brain tumors in adults to help guide diagnosis and care.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07198256

• Same-day stereotactic radiation with reduced planning margins for growing or changing brain metastases

  This trial will try to see if doing MRI planning and stereotactic radiation on the same day, with either a 0 mm or 1 mm treatment margin, helps adults with growing or unstable brain metastases stay on target and reduce side effects.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07132190

• Preventing first seizures with levetiracetam in patients with motor cortex brain metastases

  This test will try giving levetiracetam to adults with motor cortex brain metastases who have never had a seizure to see if it prevents a first seizure compared with not giving the drug.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07130786

• Avoiding brain radiation when systemic therapy already targets brain metastases

  This pilot trial tests whether patients with brain metastases who respond to systemic therapy can skip brain radiation.

  Recruiting Phase 2 University of Vermont Medical Center · Burlington, Vermont · NCT06974370

• Using ex vivo pharmacoscopy to guide treatment for brain metastases

  This project will test whether pharmacoscopy, a lab test that screens a patient's tumor cells against many drugs, can help pick effective treatments for adults having surgery for brain metastases.

  Recruiting at 2 sites Phase 2 University of Zurich · Basel and 2 other locations · NCT06620380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.